TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

AMVUTTRA

VUTRISIRAN SODIUM
Cardiovascular Approved 2022-06-13
2
Indications
--
Phase 3 Trials
1
Priority Reviews
3
Years on Market

Details

Status
Prescription
First Approved
2022-06-13
Routes
SUBCUTANEOUS
Dosage Forms
SOLUTION

Companies

Active Ingredient: VUTRISIRAN SODIUM

AMVUTTRA Approval History

Loading approval history...

What AMVUTTRA Treats

2 indications

AMVUTTRA is approved for 2 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hereditary Transthyretin-Mediated Amyloidosis
  • Cardiomyopathy
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

AMVUTTRA FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

AMVUTTRA is a transthyretin-directed small interfering RNA indicated for the treatment of: the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits 1.1 Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. 1.2 Cardiomyopathy of Wild-type or Here...

AMVUTTRA Patents & Exclusivity

Latest Patent: Jul 2036
Exclusivity: Jun 2029

Patents (13 active)

US11286486 Expires Jul 28, 2036
US10683501 Expires Jul 28, 2036
US10208307 Expires Jul 28, 2036
US12049628 Expires Jul 28, 2036
US11401517 Expires Aug 14, 2035
US10612024 Expires Aug 14, 2035
US9399775 Expires Nov 16, 2032
US10570391 Expires Nov 16, 2032
US8106022 Expires Dec 12, 2029
US9370581 Expires Dec 4, 2028
+ 3 more patents

Exclusivity

I-964 Until Mar 2028
NCE Until Jun 2027
ODE-212 Until Jun 2029
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.